DHR240726P272500
- 5.13
- 0.000.00%
Danaher Newsroom
Redburn Atlantic Adjusts Price Target on Danaher to $280 From $260
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration
Argus Research Initiates Danaher(DHR.US) With Buy Rating, Announces Target Price $300
Demystifying Danaher: Insights From 5 Analyst Reviews
Danaher Price Target Raised to $310.00/Share From $290.00 by TD Cowen
BofA Securities Maintains Danaher(DHR.US) With Hold Rating, Maintains Target Price $275
Stifel Adjusts Price Target on Danaher to $250 From $235
A Quick Look at Today's Ratings for Danaher(DHR.US), With a Forecast Between $270 to $310
Danaher Is Maintained at Neutral by B of A Securities
Express News | Danaher Corp : BofA Global Research Raises Price Objective to $275 From $270
Express News | B of A Securities Maintains Neutral on Danaher, Raises Price Target to $275
Danaher Analyst Ratings
RBC Raises Price Target on Danaher to $300 From $297, Keeps Outperform Rating
RBC Capital Remains a Buy on Danaher (DHR)
Express News | Danaher Corp. : Barclays Raises Target Price to $285 From $270
Express News | Danaher Corp : Leerink Partners Raises Target Price to $280 From $275
Decoding Danaher Corp (DHR): A Strategic SWOT Insight
Express News | Danaher Corp : JP Morgan Raises Target Price to $305 From $295
Top Gap Ups and Downs on Tuesday: SAP, DHR, DIS and More
Health Care Stocks Steady With Broader Market -- Health Care Roundup